Intranasal Pramlintide Nanoparticles: Nose-to-Brain Delivery of an Amylin Peptide Analog
Dextran-pramlintide polyelectrolyte complex nanoparticles delivered via intranasal route achieved nose-to-brain delivery, demonstrating a non-invasive approach for amylin analog therapy.
Quick Facts
What This Study Found
Dextran-pramlintide nanoparticles delivered via intranasal route achieved nose-to-brain pramlintide delivery, demonstrating a non-invasive peptide brain delivery approach.
Key Numbers
Specific dosing and cognitive test scores were not detailed in the available abstract portion.
How They Did This
Formulated pramlintide in dextran polyelectrolyte complex-coated nanoparticles. Characterized particle properties, stability, and nasal permeation. Assessed nose-to-brain delivery.
Why This Research Matters
Amylin and its analogs show promise for neurodegenerative diseases, but brain delivery is a major hurdle. Intranasal nanoparticles could make brain-targeted amylin therapy as simple as a nasal spray.
The Bigger Picture
Nose-to-brain delivery is gaining momentum as a practical route for brain-targeted peptide therapy. Combined with nanoparticle technology, it could enable non-invasive treatment of neurodegenerative diseases with peptides like amylin, insulin, and oxytocin.
What This Study Doesn't Tell Us
Preliminary delivery study. The amount of pramlintide reaching the brain via nasal route may be limited. Long-term safety of nasal nanoparticle administration needs evaluation.
Questions This Raises
- ?Could intranasal pramlintide slow Alzheimer's disease progression?
- ?How does nose-to-brain pramlintide bioavailability compare to injectable delivery?
- ?Can this nanoparticle platform deliver other peptide drugs to the brain?
Trust & Context
- Key Stat:
- Nose-to-brain peptide Pramlintide nanoparticles delivered via nasal spray reach the brain, bypassing the blood-brain barrier without injection
- Evidence Grade:
- Preliminary evidence: formulation and delivery proof-of-concept study. No clinical efficacy data for brain conditions.
- Study Age:
- Published in 2024. Advances nose-to-brain peptide delivery technology.
- Original Title:
- Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.
- Published In:
- International journal of biological macromolecules, 281(Pt 1), 136158 (2024)
- Authors:
- Zuglianello, Carine, França, Angela P, de Souza, Bruna S, Agnes, Jonathan P, Prediger, Rui D, Lemos-Senna, Elenara
- Database ID:
- RPEP-09703
Evidence Hierarchy
Frequently Asked Questions
What is pramlintide?
Pramlintide is a synthetic version of amylin, a peptide hormone normally produced alongside insulin. It's approved for diabetes but also shows neuroprotective properties, making it a candidate for treating brain diseases like Alzheimer's — if it can reach the brain.
How does nose-to-brain delivery work?
The nasal cavity has direct nerve connections to the brain (via the olfactory and trigeminal nerves). Nanoparticles sprayed into the nose can travel along these nerve pathways to reach the brain, bypassing the blood-brain barrier that blocks most drugs from entering the brain through the bloodstream.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09703APA
Zuglianello, Carine; França, Angela P; de Souza, Bruna S; Agnes, Jonathan P; Prediger, Rui D; Lemos-Senna, Elenara. (2024). Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.. International journal of biological macromolecules, 281(Pt 1), 136158. https://doi.org/10.1016/j.ijbiomac.2024.136158
MLA
Zuglianello, Carine, et al. "Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.." International journal of biological macromolecules, 2024. https://doi.org/10.1016/j.ijbiomac.2024.136158
RethinkPeptides
RethinkPeptides Research Database. "Intranasal administration of dextran-pramlintide polyelectro..." RPEP-09703. Retrieved from https://rethinkpeptides.com/research/zuglianello-2024-intranasal-administration-of-dextranpramlintide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.